The IBD therapeutic landscape is evolving with new treatment options…including early diagnosis and intervention, treat to target strategy, and control of new biomarkers. Novel therapies are appearing in clinical trials yearly, but because of the highly competitive nature of IBD drug development, not all of them are able to achieve study endpoints. The current trend in IBD drug development is a shift towards effective oral therapy, which still has pros and cons and subsequently makes conducting clinical trials more challenging than 10 years ago.
Patient recruitment and retention depends on the study protocol criteria and complexity, which must be scientifically sound to achieve the goals of the study as well as being attractive to patients. PSI provides a thorough review of the protocol by both internal therapeutic area experts and external independent consultants who are not only key opinion leaders in the therapeutic area but also active principal investigators in clinical trials. Contact us today to learn more.